Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00101972 | RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | PHASE1 | COMPLETED | 53 | — | — | Dec 1, 2004 | May 1, 2008 | Feb 22, 2022 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| RAV12 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| monoclonal antibody RAV12 | BIOLOGICAL | Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks |
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma * Metastatic or recurrent disease * Not curable by standard therapies * Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease * Patients with colorectal or breast adenocarcinoma...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |